Used in research to inhibit osteoclast fusion by targeting DC-STAMP, a key protein involved in the formation of multinucleated osteoclasts. This reference antibody, based on a patent from the University of Rochester, helps study bone resorption processes and is applied in developing therapies for osteoporosis, rheumatoid arthritis, and other bone-related diseases involving excessive osteoclast activity. It is also utilized in immunological studies to understand cell-cell fusion mechanisms and dendritic cell interactions. Due to its specificity, it serves as a reference tool in validating DC-STAMP expression in various experimental models.